A share price of Zentalis Pharmaceuticals Inc [ZNTL] is currently trading at $1.92, down -11.11%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ZNTL shares have gain 10.34% over the last week, with a monthly amount drifted -35.79%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Zentalis Pharmaceuticals Inc [NASDAQ: ZNTL] stock has seen the most recent analyst activity on August 12, 2024, when Wedbush upgraded its rating to a Neutral but kept the price target unchanged to $4 for it. Previously, UBS downgraded its rating to Neutral on June 20, 2024, and dropped its price target to $5. On June 18, 2024, downgrade downgraded it’s rating to Equal Weight. Wedbush downgraded its rating to a Underperform and decreased its price target to $4 on June 18, 2024. Morgan Stanley downgraded its rating to a Equal-Weight and reduced its price target to $8 on June 18, 2024. Jefferies downgraded its rating to Hold for this stock on June 18, 2024, and downed its price target to $6. In a note dated November 08, 2023, Wedbush downgraded an Neutral rating on this stock and revised its target price from $38 to $12.
Zentalis Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $1.61 and $18.07. Currently, Wall Street analysts expect the stock to reach $21.86 within the next 12 months. Zentalis Pharmaceuticals Inc [NASDAQ: ZNTL] shares were valued at $1.92 at the most recent close of the market. An investor can expect a potential return of 1038.54% based on the average ZNTL price forecast.
Analyzing the ZNTL fundamentals
Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -4.91%, Pretax Profit Margin comes in at -4.2%, and Net Profit Margin reading is -4.2%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is -0.44 and Total Capital is -0.53. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.8033 points at the first support level, and at 1.6867 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.1433, and for the 2nd resistance point, it is at 2.3667.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Zentalis Pharmaceuticals Inc [NASDAQ:ZNTL] is 7.29. Further, the Quick Ratio stands at 7.29, while the Cash Ratio is 0.75. Considering the valuation of this stock, the price to sales ratio is 3.37, the price to book ratio is 0.39.
Transactions by insiders
Recent insider trading involved Vultaggio Vincent, PAO and Interim PFO, that happened on Feb 03 ’25 when 2615.0 shares were sold. Chief Scientific Officer, Lackner Mark completed a deal on Feb 03 ’25 to sell 14368.0 shares. Meanwhile, Chief Legal Officer Paul Andrea sold 13230.0 shares on Feb 03 ’25.
